Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | MGAM | O43451 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | SI | P14410 | 1/20 | 0.35 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.33 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | PIK3R1 | P27986 | 3/20 | 0.32 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL426418 | 0.95 | CNR2 (0.37) | ALOX15L3MBTL1MGAMGAASI | |
| SCHEMBL1909089 | 0.95 | CNR2 (0.37) | ALOX15L3MBTL1MGAMGAASI | |
| SCHEMBL429808 | 0.85 | CNR2 (0.42) | EPHX2USP2SMN1; SMN2CNR2NR1H2 | |
| SCHEMBL34473910 | 0.85 | KMT2A (0.37) | ALOX15L3MBTL1MGAMGAASI | |
| SCHEMBL21808041 | 0.81 | KMT2A (0.34) | ALOX15L3MBTL1KMT2AEPHX2ADORA1 | |
| SCHEMBL24906856 | 0.79 | KMT2A (0.40) | ALOX15L3MBTL1MGAMGAASI | |
| SCHEMBL1909264 | 0.78 | ALOX15 (0.34) | ALOX15L3MBTL1MGAMGAASI | |
| SCHEMBL18497293 | 0.78 | KMT2A (0.39) | ALOX15L3MBTL1MGAMGAASI | |
| SCHEMBL23326750 | 0.78 | KMT2A (0.42) | ALOX15L3MBTL1MGAMGAASI | |
| SCHEMBL980372 | 0.78 | ADORA1 (0.39) | ALOX15L3MBTL1MGAMGAASI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4523755-A2 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | F. Hoffmann-La Roche AG (CH) | 2025-03-19 | — | — | EP | disclosed |
| EP-4360713-B1 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | HOFFMANN LA ROCHE (CH) | 2024-10-30 | — | — | EP | disclosed |
| CN-118255772-A | Quinazoline derivatives as antitumor agents | 苏州赞荣医药科技有限公司 | 2024-06-28 | — | — | CN | disclosed |
| EP-4360713-A2 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | F. Hoffmann-La Roche AG (CH) | 2024-05-01 | — | — | EP | disclosed |
| EP-3853220-B1 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | HOFFMANN LA ROCHE (CH) | 2024-01-03 | — | — | EP | disclosed |
| US-20230293533-A1 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | HOFFMANN-LA ROCHE INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230293533-A1 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | HOFFMANN-LA ROCHE INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230293533-A1 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | HOFFMANN-LA ROCHE INC. | 2023-09-21 | — | — | US | disclosed |
| US-11723908-B2 | Quinazoline derivatives as antitumor agents | SUZHOU ZANRONG PHARMA LIMITED (CN) | 2023-08-15 | — | — | US | disclosed |
| US-11723908-B2 | Quinazoline derivatives as antitumor agents | SUZHOU ZANRONG PHARMA LIMITED (CN) | 2023-08-15 | — | — | US | disclosed |
| US-11723908-B2 | Quinazoline derivatives as antitumor agents | SUZHOU ZANRONG PHARMA LIMITED (CN) | 2023-08-15 | — | — | US | disclosed |
| US-20210386742-A1 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | HOFFMANN-LA ROCHE INC. | 2021-12-16 | — | — | US | disclosed |
| US-20210386742-A1 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | HOFFMANN-LA ROCHE INC. | 2021-12-16 | — | — | US | disclosed |
| CN-112654612-A | Quinazoline derivatives as antitumor agents | 苏州赞荣医药科技有限公司 | 2021-04-13 | — | — | CN | disclosed |
| WO-2020057511-A1 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | SUZHOU ZANRONG PHARMA LIMITED (CN) | 2020-03-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210386742-A1 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | ABL1, TP53, JAK1 | ALOX15 3804/4885L3MBTL1 4332/4885MGAM 3877/4885 |
| US-11723908-B2 | Quinazoline derivatives as antitumor agents | ABL1, TP53, JAK1 | ALOX15 3804/4885L3MBTL1 4332/4885MGAM 3877/4885 |
| US-20230293533-A1 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | ABL1, TP53, JAK1 | ALOX15 3804/4885L3MBTL1 4332/4885MGAM 3877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.